Adventrx rises on US FDA acceptance of lung cancer drug NDA
This article was originally published in Scrip
Executive Summary
Shares of Adventrx Pharmaceuticals shot up nearly 30% 6 January after the US FDA accepted for filing the company's new drug application for Exelbine (vinorelbine injectable emulsion), formerly known as ANX-530.